EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Prophylactic use of ofloxacin in granulocytopenic patients with hematological malignancies during post-remission chemotherapy






Internal Medicine 31(3): 319-324

Prophylactic use of ofloxacin in granulocytopenic patients with hematological malignancies during post-remission chemotherapy

The prophylactic efficacy of ofloxacin (OFLX) therapy was evaluated in 51 granulocytopenic episodes in 22 patients with hematological malignancies during post-remission chemotherapy in a prospective, randomized, controlled trial. Oral administration of OFLX plus amphotericin-B (AMPH) and polymyxin-B (PL) reduced episodes of fever and infection more than did the control regimen with PL and AMPH alone (p less than 0.01), and the reduction in the incidence of infection was evident even in patients showing severe granulocytopenia (p less than 0.01). Furthermore, the first fever after the onset of granulocytopenia in the OFLX regimen developed later than that in the control regimen (p less than 0.05). Clinically, the prophylactic efficacy was 92% for the OFLX regimen and 40% for the control regimen (p less than 0.01). These findings suggest that OFLX is a promising prophylactic agent following post-remission chemotherapy. Patient hemomyelogram findings similar to those of patients with other malignancies may imply that OFLX is widely effective in granulocytopenic patients taking aggressive chemotherapy.


Accession: 041099923

PMID: 1611181

DOI: 10.2169/internalmedicine.31.319



Related references

Nomura, K.; Fujimoto, Y.; Taniguchi, K.; Shimizu, D.; Okamoto, M.; Shimura, K.; Matsumoto, Y.; Kanbayashi, Y.; Tanaka, S.; Kaneko, H.; Horiike, S.; Shimazaki, C.; Yokota, S.; Taniwaki, M., 2007: Prophylactic effect of tropisetron hydrochloride against nausea and vomiting in patients receiving chemotherapy for hematological malignancies. To establish the effectiveness of oral 5-HT(3) antagonist, oral 5 mg tropisetron was introduced in the 21 cases with hematological malignancies for the prevention of chemotherapy-induced nausea and vomiting. Nausea and vomiting did not develop in...

D.L.ma, M.; Bonamino, M.; Vasconcelos, Z.; Diamond, H.; Zalcberg, I.; Andrade, C.; Bouzas, L.; Matta, J.; Tavares, R.; Lerner, D.; Byington, R.; Silva, M.; Carvalho, L.; Pires, V.; Barone, B.; Maciel, C.; Tabak,, 1999: Moderately ablative chemotherapy, hematopoietic stem cell transplantation , and prophylactic donor lymphocyte infusions for poor prognosis patients with hematological malignancies. Blood 94(10 SUPPL 1 PART 1): 349a, Nov 15

Lim S.H.; Smith M.P.; Salooja N.; Machin S.J.; Goldstone A.H., 1991: A prospective randomized study of prophylactic teicoplanin to prevent early hickman catheter related sepsis in patients receiving intensive chemotherapy for hematological malignancies. Eighty-eight patients with haematological malignancies requiring Hickman catheters for intensive chemotherapy were randomized to receive either one single bolus intravenous injection of teicoplanin or no teicoplanin immediately before insertion of...

Fei, X.; Lei, F.; Zhang, H.; Lu, H.; Zhu, Y.; Tang, Y., 2016: Predicting early post-chemotherapy adverse events in patients with hematological malignancies: a retrospective study. The purpose of this study was to develop a mathematical model that predicts the definite adverse events following chemotherapy in patients with hematological malignancies (HMs). This is a retrospective cohort study including 1157 cases with HMs. F...

Gualtieri, R.J.; Donowitz, G.R.; Kaiser, D.L.; Hess, C.E.; Sande, M.A., 1983: Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. In a double blind study, oral prophylactic trimethoprim/sulfamethoxazole was evaluated for its utility in preventing serious infections in patients with hematologic malignancy. Of 58 evaluated granulocytopenic episodes in 47 patients, acute leukem...

Todeschini, G.; Veneri, D.; Carlini, S.; Pizzolo, G.; Ambrosetti, A.; Bonesi, R.; Cassibba, V.; Vinante, F.; Meneghini, V.; Perona, G., 1991: Ceftazidime and amikacin as empiric antibiotic therapy of febrile granulocytopenic patients with hematological malignancies. Report of 171 consecutive episodes. One hundred and seventy-one consecutive febrile episodes occurring in 130 neutropenic adult patients with hematological malignancies (mainly acute leukemia) were empirically treated with a combination antibiotic therapy consisting of ceftazidime (...

Ohnishi, K., 2011: Chemotherapy in elderly patients with hematological malignancies. A half of patients with acute myeloid leukemia and lymphoma are older than 60 years. However, using chronological age for estimating chemotherapy-related risks is unreliable, and patients without comorbidity may be candidates for the standard ther...

Sawada, H.; Tashima, M.; Okuma, M., 1991: Use of ofloxacin in prevention and treatment of secondary infections in hematological malignancies. We evaluated the effectiveness of ofloxacin (OFX) administered for prophylactic purposes during 77 episodes of neutropenia (less than 500/mm3) in 54 patients with hematological malignancies and to combat infection in 17 patients with both hematolo...

Sawada H.; Kato Y.; Okuda T.; Yumoto Y.; Tashima M.; Sasada M.; Uchino H., 1987: Treatment and prevention of secondary infections in hematological malignancies by ofloxacin. Japanese Archives of Internal Medicine 34(9): 315-321

Canet, E.; Zafrani, L.; Lambert, J.; Thieblemont, C.; Galicier, L.; Schnell, D.; Raffoux, E.; Lengline, E.; Chevret, S.; Darmon, M.; Azoulay, E., 2013: Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. Optimal chemotherapy with minimal toxicity is the main determinant of complete remission in patients with newly diagnosed hematological malignancies. Acute organ dysfunctions may impair the patient's ability to receive optimal chemotherapy. T...